Early-Stage Trials Begin for Dual COVID-19, Flu Vaccine
Novavax Incorporation announced on Monday that its combined flu and COVID-19 vaccine elicited working antibodies against the viruses in a preclinical study.
Novavax Incorporation announced on Monday that its combined flu and COVID-19 vaccine elicited working antibodies against the viruses in a preclinical study. The NanoFlu/NVX-CoV2373 vaccine elicited strong responses to both influenza A and B and protected against the SARS-CoV-2 virus.1
"Seasonal influenza and COVID-19 combination vaccines will likely be critical to combating emerging COVID-19 variants," said Russell Wilson, Novavax Executive Vice President, NanoFlu General Manager.
Animals who received the combined vaccine showed heightened levels of COVID-19 antibodies two weeks after their first immunization. This increased significantly after a second dose, compared to animals that received the COVID-19 vaccine, NVX-CoV2373, alone, the company said. Novavax said it expects to start clinical studies of the combined vaccine by the end of 2021.1-3
References
- Novavax announces Positive Preclinical data for Combination influenza and Covid-19 Vaccine candidate. Accessed September 8, 2021. http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn%3Anewsml%3Areuters.com%3A20210510%3AnPn9tWFTsa&default-theme=true
- Novavax combined influenza/COVID-19 vaccine shows promise in animal study. Reuters. Accessed September 8, 2021. https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-combined-influenzacovid-19-vaccine-shows-promise-preclinical-study-2021-05-10/
- Novavax begins early-stage trial for Combined influenza/COVID-19 vaccine. Reuters. News Release. Accessed September 8, 2021. https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-begins-early-stage-trial-combined-influenzacovid-19-vaccine-2021-09-08/
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.
